MISSISSAUGA, ONTARIO--(Marketwire - May 28, 2008) - Covalon Technologies Ltd. (TSX VENTURE: COV) is pleased to announce that it has successfully achieved another important preclinical milestone in its most significant research project, code-named EPAS-1.
